FINWIRES · TerminalLIVE
FINWIRES

Hong Kong Stocks Eke Out Gains; Metis TechBio, Impact Therapeutics Shine on Debut

By

Hong Kong stocks edged higher on Wednesday ahead of the meeting between U.S. President Donald Trump and Chinese President Xi Jinping.

The Hang Seng Index added 0.2%, or 40.53 points, to close at 26,388.44. The Hang Seng China Enterprises Index barely moved in negative territory to finish at 8,876.38.

Trump is expected to arrive in Beijing on Wednesday ahead of talks scheduled for Thursday and Friday.

The leaders of the world's two largest economies are set to hold their first face-to-face meeting in more than six months.

Discussions are expected to focus on Iran, Taiwan, artificial intelligence, and nuclear weapons, while both sides also weigh extending their critical minerals agreement.

Meanwhile, tensions in the Middle East remained unresolved after Trump said he was unlikely to seek China's assistance in ending the conflict with Iran.

In corporate news, two companies made their debut on the Hong Kong bourse.

Metis TechBio (HKG:7666) closed nearly 127% higher at HK$23.80, well above the offer price of HK$10.50.

Impact Therapeutics (HKG:7630) advanced over 108% to close at HK$41.86, compared with the offer price of HK$20.10.

Related Articles

Asia

Singapore Exchange Reports 6% Rise in Securities Market Turnover in April

Singapore Exchange (SGX:S68) reported a 6% year-over-year rise in securities market turnover to SG$43.2 billion in April, according to an after-market filing with the Singapore Exchange on Wednesday.Securities daily average value, or SDAV, also jumped 6% year over year to SG$2.1 billion, while derivatives traded volume edged up 1% on year to 30.2 million contracts, with derivatives daily average volume increasing slightly to about 1.5 million contracts.The steady trading volumes were driven by strong participation in small and mid-cap stocks, with SDAV of those stocks rising 8% month over month.Meanwhile, assets under management across exchange-traded funds or ETFs, crossed SG$20 billion in April, representing a 45% year-over-year surge.

$SGX:S68
Asia

Henlius Biotech Gets Nod for Tumor Drug Trial in Australia

Shanghai Henlius Biotech (HKG:2696) obtained approval for a phase 1 clinical trial of HLX48 for injection from Australia's relevant regulatory authorities, according to a Wednesday Hong Kong bourse filing.The drug will be tested for the treatment of advanced/metastatic solid tumors.

$HKG:2696
Asia

Kabra Extrusiontechnik Appoints Interim CFO

Kabra Extrusiontechnik (NSE:KABRAEXTRU, BOM:524109) has appointed Uttam Singh, currently the deputy general manager-accounts and finance, as the interim chief financial officer, according to a Wednesday filing to the Indian stock exchanges.His appointment is effective from Wednesday till a new CFO is appointed by the board.

$BOM:524109$NSE:KABRAEXTRU